China SXT Pharmaceuticals Inc
NASDAQ:SXTC
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
Price:
2.51
USD
-3.83%
Market Closed
Market Cap:
$2.4m
China SXT Pharmaceuticals Inc
Research & Development
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
China SXT Pharmaceuticals Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
Research & Development
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
C
|
CSPC Pharmaceutical Group Ltd
HKEX:1093
|
Research & Development
-¥5.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-40%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Research & Development
-¥2.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Research & Development
-¥305m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Research & Development
-¥7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Research & Development
-¥1.4B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
No Stocks Found
China SXT Pharmaceuticals Inc
Glance View
China Sxt Pharmaceuticals, Inc. is a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). The company is headquartered in Taizhou, Jiangsu and currently employs 96 full-time employees. The company went IPO on 2019-01-04. The firm develops, manufactures and sells three types of TCMP products: advanced TCMP, fine TCMP and regular TCMP, and TCM Homologous Supplements (TCMHS) products. The firm sells its TCMP products under three brand names such as Suxuangtang, Hui Chun Tang and Tong Ren Tang. Most of its products are sold on a prescription basis across China.
SXTC
Intrinsic Value
6.75
USD
Undervaluation 63%
